Novartis AG ADR (NVS)vsSolventum Corp. (SOLV)
NVS
Novartis AG ADR
$158.83
-0.24%
HEALTHCARE · Cap: $290.96B
SOLV
Solventum Corp.
$88.55
+2.76%
HEALTHCARE · Cap: $14.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 586% more annual revenue ($56.69B vs $8.26B). NVS leads profitability with a 22.5% profit margin vs 17.3%. SOLV appears more attractively valued with a PEG of 1.22. SOLV earns a higher WallStSmart Score of 60/100 (C).
NVS
Buy51
out of 100
Grade: C-
SOLV
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for SOLV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 29 in profit
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Revenue declined 3.0%
Earnings declined 91.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : SOLV
The strongest argument for SOLV centers on P/E Ratio, Return on Equity. Profitability is solid with margins at 17.3% and operating margin at 5.6%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SOLV
The primary concerns for SOLV are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while SOLV is a declining play — different risk/reward profiles.
SOLV carries more volatility with a beta of 0.72 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
SOLV scores higher overall (60/100 vs 51/100), backed by strong 17.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Solventum Corp.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?